The Communities Delegation to the Unitaid Board is looking to appoint a new Alternate Board Member to represent communities living with and affected by HIV, TB and malaria and those co-infected with HIV and HCV.

The Time for $5 Coalition calls out Cepheid for not including price reductions of Xpert tests in their updated GeneXpert pricing packages for low- and middle-income countries.

A pioneering study by UCL scientists has discovered the presence of a harmful inflammatory protein in patients with symptomatic tuberculosis (TB).

Risk for active tuberculosis (TB) may be reduced with the use of statins. This finding was published in a letter to the editor in the Journal of Infectious Diseases.¹

The Stop TB Partnership New Tools Working Groups and the Stop TB Partnership NGO and Affected Community Board Delegations are co-developing a self-guided online learning course on new TB drugs, diagnostics, and vaccines. The purpose of the course is to build capacity and strengthen the engagement of advocates, including TB-affected communities and civil society, in the TB research and development agenda.

The World Health Organization (WHO) is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the management of tuberculosis (TB) in children and adolescents.

A shorter regimen containing rifapentine and moxifloxacin can cure TB in four months.

An RNA signature of tuberculosis, RISK11, was used to discriminate between individuals with prevalent tuberculosis or progression to incident tuberculosis and individuals who remained healthy, according to a study in The Lancet Infectious Diseases. However, the use of 3 months of once-weekly high-dose isoniazid and rifapentine (3HP) to treat signature-positive individuals did not reduce progression to tuberculosis over 15 months.

A special Mini-Meet of the Working Group on Public-Private Mix for TB Prevention and Care (PPM Working Group) will be held virtually on 20 May 2021 in an interactive format. The meeting is open to all participants.

TAG and AfroCAB are inviting applications from treatment activists and community leaders for a new cross-disease long-acting technologies community advisory board. The deadline to apply is 21 May 2021.